Unicycive's OLC Drug Set for FDA Approval Amid Market Competition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: seekingalpha
- Drug Development Progress: Unicycive Therapeutics' next-generation phosphate binder, oxylanthanum carbonate (OLC), is set for FDA PDUFA on June 29, aiming to attract patients with unmet medical needs, particularly among chronic kidney disease patients on dialysis.
- Market Competition Analysis: While competitors like Sanofi's Renvela and Ardelyx's Xphosah exist, OLC's smaller tablet size and non-chewable formulation provide a significant advantage in patient compliance, especially given Renvela's requirement for thrice-daily dosing.
- Sales Strategy Planning: Unicycive plans to launch OLC in Q3 and will establish a sales force of approximately 60, focusing on around 2,100 physicians who prescribe hyperphosphatemia drugs, particularly targeting practices near dialysis centers to enhance market penetration.
- Payment System Impact: OLC will be covered under the TDAPA system at 100% of the average sale price for new therapies, followed by a three-year add-on payment at 65%, transitioning to standard ESRD bundled payments after five years, ensuring market stability and sustainability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNCY
Wall Street analysts forecast UNCY stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.690
Low
21.00
Averages
35.80
High
60.00
Current: 4.690
Low
21.00
Averages
35.80
High
60.00
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Unicycive's Drug Faces Second FDA Rejection
- FDA Rejection: Unicycive's drug oxylanthanum carbonate (OLC) faced a second rejection from the FDA due to third-party manufacturing deficiencies rather than clinical safety or efficacy issues, resulting in a 39% drop in stock price in a single day.
- Analysts Maintain Ratings: Despite the FDA's rejection, both B. Riley and H.C. Wainwright maintained their 'Buy' ratings on UNCY, with B. Riley setting a price target of $22 and H.C. Wainwright lowering it to $15, reflecting confidence in the company's long-term commercial prospects.
- Active FDA Engagement: Unicycive stated it is in active discussions with the FDA, optimistic about a successful inspection of the third-party manufacturer and plans to expeditiously resubmit the New Drug Application (NDA), indicating continued confidence in the drug's efficacy and safety.
- Retail Sentiment Optimistic: Despite the stock's decline, retail investor sentiment on Stocktwits remains in the 'extremely bullish' territory, with some users expressing optimism about eventual drug approval, highlighting market expectations for the company's future.
See More
Unicycive Receives Complete Response Letter from FDA
- FDA Response Letter: Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for oxylanthanum carbonate, indicating that the FDA did not raise concerns about clinical efficacy or safety data, and no additional data was requested, reflecting recognition of the product's potential.
- Inspection Delays: The FDA has not yet conducted an inspection of the third-party manufacturer, which aligns with deficiencies noted in the previous CRL issued in June 2025, indicating ongoing challenges for Unicycive in resolving these issues that could impact the NDA approval timeline.
- Clinical Research Support: The NDA for OLC is supported by data from three clinical studies, including a Phase 1 study in healthy volunteers and a tolerability study in CKD patients, demonstrating its potential in treating hyperphosphatemia and possibly improving patient adherence to treatment.
- Future Outlook: Unicycive's CEO expressed confidence in the efficacy and safety of OLC and is actively discussing labeling and packaging with the FDA, anticipating a successful inspection of the third-party manufacturer and a swift resubmission of the NDA, showcasing the company's optimistic outlook for the future.
See More
Block & Leviton Investigates Unicycive Therapeutics for Securities Violations
- Investigation Background: Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations, specifically whether the company made false or misleading statements to investors or failed to disclose material information regarding the FDA's review of its OLC New Drug Application.
- FDA Response: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter for its resubmitted OLC NDA, citing the same third-party manufacturing deficiencies identified in a prior Complete Response Letter from June 2025, which led to a decline in the company's stock price.
- Investor Rights: Any investor who purchased Unicycive stock and experienced losses is encouraged to contact Block & Leviton to learn how they might recover those losses, demonstrating the firm's commitment to protecting investor interests.
- Whistleblower Program: Block & Leviton invites whistleblowers with non-public information to assist in the investigation, stating that those who provide original information to the SEC may receive rewards of up to 30% of any successful recovery, thereby enhancing the appeal for investor cooperation.
See More
Unicycive Therapeutics Shares Plunge 37% After FDA Response
- FDA Complete Response Letter: Unicycive Therapeutics announced it received a Complete Response Letter from the FDA regarding its resubmitted NDA, resulting in a ~37% drop in stock price during Tuesday afternoon trading, indicating significant setbacks in the drug development for treating hyperphosphatemia in chronic kidney disease patients.
- Manufacturing Issues Impact: This response letter is linked to another Complete Response Letter received in June 2025 concerning manufacturing issues at a third-party site, highlighting ongoing challenges in production compliance that could affect the company's competitive position in the market.
- Reinspection Failure: The FDA was unable to re-inspect the manufacturing site by the action date of June 26, indicating a lack of confidence from regulators in the facility, which may lead to further delays and uncertainties impacting the company's future product launch plans.
- Intensifying Market Competition: Unicycive CEO Shalabh Gupta mentioned in a recent interview that despite these challenges, OLC aims to distinguish itself in the crowded hyperphosphatemia market, reflecting the company's optimistic outlook on its product's market potential despite current regulatory hurdles.
See More
Unicycive Therapeutics Under Investigation Following FDA Response, Stock Declines
- FDA Response Impact: On June 30, 2026, Unicycive Therapeutics announced that the FDA issued a second Complete Response Letter regarding its resubmitted OLC NDA, indicating unresolved third-party manufacturing deficiencies, which led to a decline in stock price and investor confidence.
- Investigation Initiated: Johnson Fistel, PLLP is investigating whether Unicycive made false or misleading statements or failed to disclose material information related to the FDA review process, potentially affecting the recoverability of investor losses.
- Investor Losses: Investors who suffered losses after purchasing Unicycive securities are encouraged to contact Johnson Fistel for more information about the investigation, highlighting the firm's commitment to protecting investor rights and possibly leading to further legal actions.
- Ongoing Regulatory Scrutiny: Unicycive disclosed that the FDA has not yet inspected its third-party manufacturer, and this revelation may exacerbate market concerns regarding the company's future compliance, impacting its long-term strategic development.
See More
Unicycive Faces Second FDA Rejection for Kidney Drug
- Regulatory Setback: Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA for its kidney drug candidate Oxylanthanum Carbonate, indicating that the drug cannot be approved in its current form, which led to a more than 45% drop in share price on Tuesday.
- Manufacturing Deficiencies: The CRL is linked to previously identified deficiencies at a third-party manufacturing facility rather than concerns about the drug's safety or efficacy, highlighting the complexities of the regulatory process despite no FDA concerns regarding clinical data.
- Financial Stability: Unicycive reported having $57.1 million in cash and equivalents, expected to fund operations into 2027, although the new CRL could alter the company's outlook and introduce additional uncertainties.
- Market Sentiment Fluctuations: Despite the significant stock decline, retail sentiment on Stocktwits remains in the 'extremely bullish' territory with message volumes surging over 380%, although some users predict a further 25% drop in stock price, indicating market concerns about future performance.
See More
Unicycive's Drug Faces Second FDA Rejection
- FDA Rejection: Unicycive's drug oxylanthanum carbonate (OLC) faced a second rejection from the FDA due to third-party manufacturing deficiencies rather than clinical safety or efficacy issues, resulting in a 39% drop in stock price in a single day.
- Analysts Maintain Ratings: Despite the FDA's rejection, both B. Riley and H.C. Wainwright maintained their 'Buy' ratings on UNCY, with B. Riley setting a price target of $22 and H.C. Wainwright lowering it to $15, reflecting confidence in the company's long-term commercial prospects.
- Active FDA Engagement: Unicycive stated it is in active discussions with the FDA, optimistic about a successful inspection of the third-party manufacturer and plans to expeditiously resubmit the New Drug Application (NDA), indicating continued confidence in the drug's efficacy and safety.
- Retail Sentiment Optimistic: Despite the stock's decline, retail investor sentiment on Stocktwits remains in the 'extremely bullish' territory, with some users expressing optimism about eventual drug approval, highlighting market expectations for the company's future.
See More
Unicycive Receives Complete Response Letter from FDA
- FDA Response Letter: Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for oxylanthanum carbonate, indicating that the FDA did not raise concerns about clinical efficacy or safety data, and no additional data was requested, reflecting recognition of the product's potential.
- Inspection Delays: The FDA has not yet conducted an inspection of the third-party manufacturer, which aligns with deficiencies noted in the previous CRL issued in June 2025, indicating ongoing challenges for Unicycive in resolving these issues that could impact the NDA approval timeline.
- Clinical Research Support: The NDA for OLC is supported by data from three clinical studies, including a Phase 1 study in healthy volunteers and a tolerability study in CKD patients, demonstrating its potential in treating hyperphosphatemia and possibly improving patient adherence to treatment.
- Future Outlook: Unicycive's CEO expressed confidence in the efficacy and safety of OLC and is actively discussing labeling and packaging with the FDA, anticipating a successful inspection of the third-party manufacturer and a swift resubmission of the NDA, showcasing the company's optimistic outlook for the future.
See More
Block & Leviton Investigates Unicycive Therapeutics for Securities Violations
- Investigation Background: Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations, specifically whether the company made false or misleading statements to investors or failed to disclose material information regarding the FDA's review of its OLC New Drug Application.
- FDA Response: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter for its resubmitted OLC NDA, citing the same third-party manufacturing deficiencies identified in a prior Complete Response Letter from June 2025, which led to a decline in the company's stock price.
- Investor Rights: Any investor who purchased Unicycive stock and experienced losses is encouraged to contact Block & Leviton to learn how they might recover those losses, demonstrating the firm's commitment to protecting investor interests.
- Whistleblower Program: Block & Leviton invites whistleblowers with non-public information to assist in the investigation, stating that those who provide original information to the SEC may receive rewards of up to 30% of any successful recovery, thereby enhancing the appeal for investor cooperation.
See More
Unicycive Therapeutics Shares Plunge 37% After FDA Response
- FDA Complete Response Letter: Unicycive Therapeutics announced it received a Complete Response Letter from the FDA regarding its resubmitted NDA, resulting in a ~37% drop in stock price during Tuesday afternoon trading, indicating significant setbacks in the drug development for treating hyperphosphatemia in chronic kidney disease patients.
- Manufacturing Issues Impact: This response letter is linked to another Complete Response Letter received in June 2025 concerning manufacturing issues at a third-party site, highlighting ongoing challenges in production compliance that could affect the company's competitive position in the market.
- Reinspection Failure: The FDA was unable to re-inspect the manufacturing site by the action date of June 26, indicating a lack of confidence from regulators in the facility, which may lead to further delays and uncertainties impacting the company's future product launch plans.
- Intensifying Market Competition: Unicycive CEO Shalabh Gupta mentioned in a recent interview that despite these challenges, OLC aims to distinguish itself in the crowded hyperphosphatemia market, reflecting the company's optimistic outlook on its product's market potential despite current regulatory hurdles.
See More
Unicycive Therapeutics Under Investigation Following FDA Response, Stock Declines
- FDA Response Impact: On June 30, 2026, Unicycive Therapeutics announced that the FDA issued a second Complete Response Letter regarding its resubmitted OLC NDA, indicating unresolved third-party manufacturing deficiencies, which led to a decline in stock price and investor confidence.
- Investigation Initiated: Johnson Fistel, PLLP is investigating whether Unicycive made false or misleading statements or failed to disclose material information related to the FDA review process, potentially affecting the recoverability of investor losses.
- Investor Losses: Investors who suffered losses after purchasing Unicycive securities are encouraged to contact Johnson Fistel for more information about the investigation, highlighting the firm's commitment to protecting investor rights and possibly leading to further legal actions.
- Ongoing Regulatory Scrutiny: Unicycive disclosed that the FDA has not yet inspected its third-party manufacturer, and this revelation may exacerbate market concerns regarding the company's future compliance, impacting its long-term strategic development.
See More
Unicycive Faces Second FDA Rejection for Kidney Drug
- Regulatory Setback: Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA for its kidney drug candidate Oxylanthanum Carbonate, indicating that the drug cannot be approved in its current form, which led to a more than 45% drop in share price on Tuesday.
- Manufacturing Deficiencies: The CRL is linked to previously identified deficiencies at a third-party manufacturing facility rather than concerns about the drug's safety or efficacy, highlighting the complexities of the regulatory process despite no FDA concerns regarding clinical data.
- Financial Stability: Unicycive reported having $57.1 million in cash and equivalents, expected to fund operations into 2027, although the new CRL could alter the company's outlook and introduce additional uncertainties.
- Market Sentiment Fluctuations: Despite the significant stock decline, retail sentiment on Stocktwits remains in the 'extremely bullish' territory with message volumes surging over 380%, although some users predict a further 25% drop in stock price, indicating market concerns about future performance.
See More
